An open letter from Eli Lilly and Company warning of potential patient safety risks associated with tirzepatide compounded with vitamin B12 - Eli Lilly and Company

The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.

You will be redirected in 10 seconds.